Cargando…

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma

BACKGROUND: The optimal duration of immune checkpoint blockade (ICB) therapy is not well established. Active residual disease is considered prohibitive for treatment discontinuation and its detection by diagnostic CT imaging is limited. Here, we set out to determine the potential added value of 2-[1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferdinandus, Justin, Zaremba, Anne, Zimmer, Lisa, Umutlu, Lale, Seifert, Robert, Barbato, Francesco, Ugurel, Selma, Chorti, Eleftheria, Grünwald, Viktor, Herrmann, Ken, Schadendorf, Dirk, Fendler, Wolfgang Peter, Livingstone, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817553/ https://www.ncbi.nlm.nih.gov/pubmed/35123578 http://dx.doi.org/10.1186/s40644-022-00449-3

Ejemplares similares

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
por: Zaremba, Anne, et al.
Publicado: (2019)

FDG-PET Positivity and Overall Survival in Renal Cell Carcinoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
por: Weber, Manuel, et al.
Publicado: (2021)

Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy
por: Ferdinandus, Justin, et al.
Publicado: (2021)

Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial
por: Seifert, Robert, et al.
Publicado: (2022)

Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
por: Matull, Johanna, et al.
Publicado: (2020)

(18)F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis
por: Deuschl, Cornelius, et al.
Publicado: (2020)

Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital system
por: Fragoso Costa, Pedro, et al.
Publicado: (2022)

Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival
por: Thielmann, Carl Maximilian, et al.
Publicado: (2022)

Evaluation of (18)F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision
por: Weber, Manuel, et al.
Publicado: (2021)

[(18)F]FDG PET/MRI in children suffering from lymphoma: does MRI contrast media make a difference?
por: Jannusch, Kai, et al.
Publicado: (2023)

Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast (18)F-FDG PET/MRI compared to (18)F-FDG PET/CT and CT
por: Kirchner, Julian, et al.
Publicado: (2017)

N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [(18)F]FDG PET/CT compared to the histopathology reference standard
por: Hautzel, Hubertus, et al.
Publicado: (2021)

18 F-FDG-PET/MRI in patients with Graves’ orbitopathy.
por: Weber, Manuel, et al.
Publicado: (2021)

Diagnostic accuracy of (18)F–FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma
por: Ruhlmann, Verena, et al.
Publicado: (2017)

Free-breathing 3D Stack of Stars GRE (StarVIBE) sequence for detecting pulmonary nodules in (18)F-FDG PET/MRI
por: Bruckmann, Nils Martin, et al.
Publicado: (2022)

Accuracy of [(18)F]FDG PET/MRI for the Detection of Liver Metastases
por: Beiderwellen, Karsten, et al.
Publicado: (2015)

Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients
por: Bruckmann, Nils Martin, et al.
Publicado: (2021)

Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Equivalent tumor detection for early and late FAPI-46 PET acquisition
por: Ferdinandus, J., et al.
Publicado: (2021)

Conventional Imaging, MRI and (18)F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast Cancer
por: Morawitz, Janna, et al.
Publicado: (2023)

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
por: Knispel, Sarah, et al.
Publicado: (2020)

Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from (68)Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient
por: Weber, Manuel, et al.
Publicado: (2020)

(18) F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine
por: Kirchner, Julian, et al.
Publicado: (2017)

Prospective evaluation of whole-body MRI and (18)F-FDG PET/MRI in N and M staging of primary breast cancer patients
por: Bruckmann, Nils Martin, et al.
Publicado: (2020)

Comparison of nodal staging between CT, MRI, and [(18)F]-FDG PET/MRI in patients with newly diagnosed breast cancer
por: Morawitz, Janna, et al.
Publicado: (2021)

Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Umutlu, Lale, et al.
Publicado: (2022)

(18)F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET?
por: Li, Yan, et al.
Publicado: (2020)

Kutanes Angiosarkom mit klinischem Bild eines Quincke-Ödems
por: Albrecht, M., et al.
Publicado: (2021)

Utility of Integrated PET/MRI for the Primary Diagnostic Work-Up of Patients with Ewing Sarcoma: Preliminary Results
por: Chodyla, Michal, et al.
Publicado: (2022)

Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancer
por: Kersting, David, et al.
Publicado: (2021)

First experiences with dynamic renal [(68)Ga]Ga-DOTA PET/CT: a comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rate
por: Kersting, David, et al.
Publicado: (2022)

Evaluation of the Predictive Potential of 18F-FDG PET and DWI Data Sets for Relevant Prognostic Parameters of Primary Soft-Tissue Sarcomas
por: Chodyla, Michal, et al.
Publicado: (2021)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

Silicon-photomultiplier-based PET/CT reduces the minimum detectable activity of iodine-124
por: Kersting, David, et al.
Publicado: (2021)

Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival
por: Schank, Timo E., et al.
Publicado: (2021)

Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy
por: Bolz, Saskia, et al.
Publicado: (2021)

Multiparametric Integrated (18)F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding
por: Umutlu, Lale, et al.
Publicado: (2021)

COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates
por: Lodde, Georg C., et al.
Publicado: (2022)

Impact of EBUS-TBNA in addition to [(18)F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC
por: Guberina, Maja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nl39vfvqk9rmf0u8bh2hl0305q